15-deoxy-δ-12,14-prostaglandin j-2

Compound 8 can bind to GID1， By the results of the in vitro binding assays, chemical 8 showed greater effects than did 67D in an in vivo experimental system.

2-Aminopurine-9-beta-D-(2’-deoxy)riboside is a derivative of 2-Aminopurine.

ANGIOTENSIN IV TFA is a less effective agonist at the angiotensin AT1 receptor.

2'-Deoxy-2'-fluoroarabinoadenosine is a nucleoside analogue with extensive anti-tumor activity and can be used for the study of tumor diseases.

2’-Deoxy-2’-fluoro-β-D-arabinocytidine hydrochloride is a cytosine nucleoside analog with inhibitory effects on DNA methyltransferase , with potential antimetabolic and antitumor activity.

2'-Deoxy-2'-fluoro-beta-D-arabinoguanosine is a purine nucleoside analog with a broad spectrum of antitumor activity, targeting malignant tumors of the inert lymphatic system and inducing apoptosis. The anticancer mechanism of 2'-Deoxy-2'-fluoro-beta-D-arabinoguanosine is dependent on the inhibition of DNA synthesis.

2’-Deoxy-N4-methylcytidine (N(3)-Methyl-2'-deoxycytidine) is a purine nucleoside analog with potential antitumor activity for the study of apoptosis.

2'',3''-Di-O-acetyl-5''-deoxy-5-fuluro-D-cytidine is a derivative of capecitabine.

5'-Deoxy-5-fluoro-N-[(pentyloxy)carbonyl]cytidine 2',3'-diacetate is an intermediate in the synthesis of capecitabine.

2',5-Difluoro-2'-deoxy-1-arabinosyluracil (2'-Deoxy-2'-fluoro-5-fluoro-arabinouridine) is a urinary pyrimidine nucleoside analogue with potential antiepileptic and antihypertensive activity, which can be used to study anticonvulsant and anxiety disorders.

2-Deoxy-D-glucose (2-DG) is an analog of glucose, an inhibitor of glycolysis. 2-Deoxy-D-glucose has antiviral activity, as well as inhibitory cell proliferation and apoptosis-inducing activity.

2-deoxy-D-Glucose-13C6is intended for use as an internal standard for the quantification of 2-deoxy-D-glucose by GC- or LC-MS. 2-deoxy-D-Glucose is a glucose antimetabolite and an inhibitor of glycolysis.1,2It inhibits hexokinase, the enzyme that converts glucose to glucose-6-phosphate, as well as phosphoglucose isomerase, the enzyme that converts glucose-6-phosphate to fructose-6-phosphate.32-deoxy-D-Glucose (16 mM) induces apoptosis in SK-BR-3 cells, as well as inhibits the growth of 143B osteosarcoma cells cultured under hypoxic conditions when used at a concentration of 2 mg/ml.4,5In vivo, 2-deoxy-D-glucose (500 mg/kg) reduces tumor growth in 143B osteosarcoma and MV522 non-small cell lung cancer mouse xenograft models when used alone or in combination with doxorubicin or paclitaxel .6 1.Kang, H.T., and Hwang, E.S.2-Deoxyglucose: An anticancer and antiviral therapeutic, but not any more a low glucose mimeticLife Sci.78(12)1392-1399(2006) 2.Aft, R.L., Zhang, F.W., and Gius, D.Evaluation of 2-deoxy-D-glucose as a chemotherapeutic agent: Mechanism of cell deathBr. J. Cancer87(7)805-812(2002) 3.Ralser, M., Wamelink, M.M., Struys, E.A., et al.A catabolic block does not sufficiently explain how 2-deoxy-D-glucose inhibits cell growthProc. Natl. Acad. Sci. USA105(46)17807-17811(2008) 4.Liu, H., Savaraj, N., Priebe, W., et al.Hypoxia increases tumor cell sensitivity to glycolytic inhibitors: A strategy for solid tumor therapy (Model C)Biochem. Pharmacol.64(12)1745-1751(2002) 5.Zhang, X.D., Deslandes, E., Villedieu, M., et al.Effect of 2-deoxy-D-glucose on various malignant cell lines in vitroAnticancer Res.26(5A)3561-3566(2006) 6.Maschek, G., Savaraj, N., Priebe, W., et al.2-deoxy-D-glucose increases the efficacy of adriamycin and paclitaxel in human osteosarcoma and non-small cell lung cancers in vivoCancer Res.64(1)31-34(2004)

1-Stearoyl-2-15(S)-HpETE-sn-glycero-3-PC is a phospholipid that contains stearic acid at the sn-1 position and 15(S)-HpETE at the sn-2 position. It is produced via oxidation of 1-stearoyl-2-arachidonoyl-sn-glycero-3-PC by 15-lipoxygenase (15-LO). 1-Stearoyl-2-15(S)-HpETE-sn-glycero-3-PC is toxic to human umbilical vein endothelial cells (HUVECs) when used at a concentration of 100 μM.

Bimatoprost is the Allergan trade name for 17-phenyl trinor prostaglandin F2α ethyl amide (17-phenyl trinor PGF2α ethyl amide), an F-series PG analog which has been approved for use as an ocular hypotensive drug. Oxidation of the C-15 hydroxyl group produces 15-keto-17-phenyl trinor PGF2α ethyl amide. 15-keto-17-phenyl trinor PGF2α ethyl amide is a potential metabolite of 17-phenyl trinor PGF2α ethyl amide when 17-phenyl trinor PGF2α ethyl amide is administered to intact animals. No pharmacological studies on 15-keto-17-phenyl trinor PGF2α ethyl amide have been reported.

11-deoxy PGF1α is a synthetic analog of PGF1α. In whole animal studies, a dose of 32 mg/kg inhibited gastric acid secretion by 35%. 11-deoxy PGF1α is also known to cause rat uterine contractions at a dose 0.3 times that of PGF1α. It also exhibits vasopressor and bronchoconstrictor activities at about half the potency of PGF2α in guinea pigs.

1-Stearoyl-2-15(S)-HpETE-sn-glycero-3-PE is a phospholipid that contains stearic acid at the sn-1 position and 15(S)-HpETE at the sn-2 position. It is produced via oxidation of 1-stearoyl-2-arachidonoyl-sn-glycero-3-PE by 15-lipoxygenase (15-LO). 1-Stearoyl-2-15(S)-HpETE-sn-glycero-3-PE (0.6 and 0.9 μM) increases ferroptotic cell death in wild-type and Acsl4 knockout Pfa1 mouse embryonic fibroblasts (MEFs) treated with the GPX4 inhibitor RSL3.

Stevia impurity (13-[(2-O-6-deoxy-β-D-glucopyranosyl-3-O-β-D-glucopyranosyl-β-D-glucopyranosyl)oxy]ent-kaur-16-en-19-oic acid β-D-glucopyranosyl ester) is a natural product for research related to life sciences. The catalog number is TN6498 and the CAS number is 1309929-72-3.

Bimatoprost is an F-series prostaglandin (PG) analog which has been approved for use as an ocular hypotensive drug. Oxidation of the C-15 hydroxyl group and amide hydrolysis of Bimatoprost produces 15-keto-17-phenyl trinor PGF2α. 15-keto-17-phenyl trinor PGF2α is a potential metabolite of bimatoprost when administered to animals. 15-keto PG analogs are potential minor impurities in commercial preparations of their corresponding bulk drug compounds. Although much less potent that the parent compound, 15-keto PGs still retain the ability to produce a small but measurable decrease (1 mm Hg) in the intraocular pressure of normal cynomolgus monkeys when administered at a dose of 1 μg/eye. 15-keto Latanoprost (15-keto-17-phenyl-13,14-dihydro trinor PGF2α isopropyl ester) is a miotic in the normal cat eye, causing an 8 mm reduction in pupillary diameter at 5 μg/eye. Again, this is not as potent as many other F-type PGs; for example, PGF2α will produce this degree of miosis at a dose of less than 1 μg/eye.

Prostaglandin D1 (PGD1) is the theoretical D-series metabolite of dihomo-γ-linolenic acid (DGLA), but to date it has not been isolated as a natural product. It is an inhibitor of ADP-induced platelet aggregation in humans with an IC50 value of 320 ng/ml, about 1/10 as potent as PGD2. 13,14-dihydro-15-keto Prostaglandin D1 (13,14-dihydro-15-keto PGD1) is the theoretical metabolite of PGD1 via the 15-hydroxy PG dehydrogenase metabolic pathway. No biological studies for this compound have been reported.

11R,12-Dihydroxyspirovetiv-1(10)-en-2-one is a natural product for research related to life sciences. The catalog number is TN2593 and the CAS number is 62574-30-5.

11-deoxy Prostaglandin E2 (11-deoxy PGE2) is a stable, synthetic analog of PGE2 . In contrast to PGE2 which has bronchodilation effects, 11-deoxy PGE2 is a powerful bronchoconstrictor and contracts human respiratory tract smooth muscle with potencies ranging from 5 to 30 times higher than PGF2α .

Bcl-2-IN-12 (Compound 1) is a potent Bcl-2 inhibitor with an IC50 value of 6 nM, utilized in cancer research [1].

9(Z),12(Z),15(Z),18(Z),21(Z)-Tetracosapentaenoic acid is an ω-3 very long-chain polyunsaturated fatty acid. It has been used to study the desaturation and elongation of ω-3 polyunsaturated fatty acids. It is elongated to form C26:5 or acted on by δ6 desaturase to form C24:6. 9(Z),12(Z),15(Z),18(Z),21(Z)-Tetracosapentaenoic acid is found at low levels in mouse brain and spleen and levels decrease in the brain and spleen of old and exceptionally old mice.

13,14-dihydro-15-keto Prostaglandin E2 (13,14-dihydro-15-keto PGE2) serves as the predominant metabolite of PGE2 in plasma, created through a 15-keto PGE2 intermediate by the action of 15-oxo-PG Δ13 reductase. Unlike its precursor PGE2, this compound exhibits poor binding affinity towards EP2 and EP4 PGE2 receptors (Ki values of 12 and 57 µM, respectively) in CHO cells and fails to stimulate adenylate cyclase activity therein (EC50s >18 and >38 µM, respectively). Concentrations of 13,14-dihydro-15-keto PGE2 are notably higher in the plasma of pregnant women during their third trimester and at labor and delivery stages, whereas its levels are found to be reduced in the tumor tissues of patients with non-small cell lung cancer (NSCLC) compared to adjacent healthy tissue.

SARS-CoV-2 Mpro-IN-12 (compound D026) serves as an inhibitor of the main protease (Mpro) of SARS-CoV-2, exhibiting antiviral properties [1].

Bcl-2-IN-15 (Compound 13d) is a Bcl-2 inhibitor with an IC50 of 363 nM, which impedes the proliferation of the NCI leukemia cancer cell line [1].

11-deoxy PGF1β is a synthetic analog of PGF1β. In contrast to PGF2α and PGF1α, 11-deoxy PGF1β exhibits vasodepressor and bronchodilator activities in guinea pigs at a dose of 500 μg/kg.

15-keto PGF1α is the initial metabolite of PGF1α via 15-hydroxy PGDH. In mammals, oxidation of C-15 markedly attenuates receptor binding and activity. In fish, the 15-keto compounds serve as post-ovulatory pheromones and are more active than the parent prostaglandins.

2-Deoxy-lyxo-hexose is a bioactive chemical.

2-Deacetoxydecinnamoyltaxinine J is a natural product from Taxus cuspidta Sibe et Zucc.

1-Stearoyl-2-15(S)-HETE-sn-glycero-3-PC is a phospholipid that contains stearic acid at the sn-1 position and 15(S)-HETE at the sn-2 position. It is produced via oxidation of 1-stearoyl-2-arachidonoyl-sn-glycero-3-PC by 15-lipoxygenase (15-LO).

Sialic acids, commonly present as terminal carbohydrates on glycoconjugates, are essential for a variety of cellular functions including cell adhesion and signal recognition, as well as the formation and progression of tumors. 3-Deoxy-D-glycero-D-galacto-2-nonulosonic acid is a deaminated sialic acid that was first identified at the nonreducing ends of oligosialyl chains in rainbow trout egg glycoprotein.[1] It is thought to be a precursor for the biosynthesis of other members of the sialic acid family.[2] 3-Deoxy-D-glycero-D-galacto-2-nonulosonic acid can be used to analyze nonulosonic acid residues in polysialoglycoproteins.[1]

SARS-CoV-2 3CLpro-IN-15 (compound a), a beta-nitrostyrene derivative, acts as an inhibitor of the SARS-CoV-2 3CL protease (3CLpro), effectively inhibiting viral replication and transcription. It is instrumental in the identification of potential anti-COVID-19 lead compounds [1].

(Rac)-Phorbol-12-(2-methylbutyrate), a natural product, can be isolated from croton oil [1].

11S,12-Dihydroxyspirovetiv-1(10)-en-2-one is a natural product for research related to life sciences. The catalog number is TN2594 and the CAS number is 62623-86-3.

2'-Deoxy-2'-fluorouridine serves as an intermediate in the synthesis of antiviral agents targeting influenza viruses[1].

9-deoxy-9-methylene Prostaglandin E2 (9-deoxy-9-methylene PGE2) is a stable, isosteric analog of PGE2 . 9-deoxy-9-methylene PGE2 retains the biological profile of PGE2 with fewer side effects. In the rat 9-deoxy-9-methylene PGE2 is equipotent to PGE2 in decreasing blood pressure. It also stimulates the gerbil colon and primate uterus at the same potency as PGE2.

Nucleoside Derivatives - 2’-Modified nucleosides, 8-Modified purine nucleosides, Halo-nucleosides, Fluoro-modified nucleosides

3',5'-Di-O-acetyl-2'-deoxy-5,N3-dimethyl uridine is a Nucleoside Derivative - N-Alkylated nucleoside.

Nucleoside Derivatives - 6-Modified purine nucleosides; Halo-nucleosides; Fluoro-modified nucleosides

Isocytidine derivative; fluoro-modified nucleoside

11-Deoxy-16,16-dimethyl Prostaglandin E2 (11-deoxy-16,16-dimethyl PGE2) is a stable synthetic analog of Prostaglandin E2 (PGE2), acting as an agonist for both EP2 and EP3 receptors. It effectively inhibits gastric acid secretion and ulcer formation in rats, with ED50 values of 1 mg/kg and 0.021 mg/kg, respectively. This compound is also 900 times more potent than Prostaglandin F2α (PGF2α) in inducing contraction of human respiratory tract smooth muscle in vitro.

19(R)-Hydroxylated prostaglandins (PGs) are present at µg/ml concentrations in the semen of some mammalian species, notably primates, with the majority being from the PGE series and featuring a 15(S),19(R) hydroxyl stereochemistry. These compounds are also observed in marsupials' seminal plasma, where F-type 1 and 2-series compounds are predominant. The 15(R)-hydroxy epimer represents the inverse or unnatural isomer at C-15 for these 19-hydroxylated PGs. Although the biological function of 19(R)-hydroxylated PGs remains unclear, 19(R)-hydroxylation in the F-series leads to a notable reduction in receptor-mediated biological activity in certain assays.

8-iso-15(R)-Prostaglandin F2α (8-iso-15(R) PGF2α) is a chemically distinct member within a broad group of prostaglandin-like eicosanoids, produced through the free radical peroxidation of arachidonic acid contained in membrane phospholipids. It represents the C-15 epimer of 8-isoPGF2α, distinguished as the sole isoprostane isomer extensively examined across numerous biological systems.

12(Z),15(Z)-Heneicosadienoic acid, an ω-6 very long-chain polyunsaturated fatty acid, serves as a positional isomer of heneicosadienoic acid, which is scarcely found in living organisms.

5'-Deoxy-5'-N-(2-chloroethyl)aminothymidine is a Nucleoside Derivative - 5'-Modified nucleoside.

Nucleoside Derivatives - 6-Modified purine nucleosides; Drugs and Inhibitors; Prodrug of anticancer agent 6-methylpurine; used for gene therapy

Nucleoside Derivatives - 8-Aza-7-deaza-purine nucleoside

13,14-dihydro-15-keto Prostaglandin E1 inhibits ADP-induced platelet aggregation in human isolated platelet-rich plasma (IC50=14.8 μg/mL) and is a PGE1 metabolite.